Literature DB >> 17675172

Atypical antipsychotics attenuate a sub-chronic PCP-induced cognitive deficit in the novel object recognition task in the rat.

B Grayson1, N F Idris, J C Neill.   

Abstract

The novel object recognition (NOR) task is a paradigm employed to detect both disruption and improvement of non-spatial memory in rats. PCP (phencyclidine) may be used to model aspects of schizophrenia symptomology in rats, in particular cognitive deficits. The aim of this study was to investigate the ability of typical and atypical antipsychotics to improve a sub-chronic PCP-induced impairment in cognition using the NOR task. Female hooded-Lister rats (195+/-12 g) received either vehicle (0.9% saline twice daily) or PCP (2 mg/kg, twice daily) for 7 days followed by 7-days drug free. Haloperidol (0.05 and 0.075 mg/kg), clozapine (1 and 5mg/kg), risperidone (0.05, 0.1 and 0.2 mg/kg) or vehicle (veh, saline) was administered i.p. 30 min prior to testing. Rats completed an acquisition trial followed by an inter-trial interval of 1 min, then a retention trial. Following sub-chronic vehicle treatment, rats spent significantly (p<0.05) more time exploring the novel compared to the familiar object, an effect that was abolished in the sub-chronic PCP treated animals. Clozapine (1.0 and 5.0 mg/kg) and risperidone (0.2 mg/kg) but not haloperidol significantly attenuated the PCP-induced impairment such that animals again spent significantly more time exploring the novel compared with familiar object (p<0.05). These results support our earlier work showing that acute PCP induces a robust object recognition deficit in female rats. Clozapine and risperidone but not haloperidol showed efficacy to reverse the deficit induced by sub-chronic PCP suggesting that this test may have some validity for assessing efficacy for improvement of cognitive deficit symptoms of schizophrenia.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17675172     DOI: 10.1016/j.bbr.2007.06.012

Source DB:  PubMed          Journal:  Behav Brain Res        ISSN: 0166-4328            Impact factor:   3.332


  72 in total

1.  Discovery of potential antipsychotic agents possessing pro-cognitive properties.

Authors:  Jelveh Lameh; Krista McFarland; Jorgen Ohlsson; Fredrik Ek; Fabrice Piu; Ethan S Burstein; Ali Tabatabaei; Roger Olsson; Stefania Risso Bradley; Douglas W Bonhaus
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2011-11-15       Impact factor: 3.000

Review 2.  Spontaneous object recognition and its relevance to schizophrenia: a review of findings from pharmacological, genetic, lesion and developmental rodent models.

Authors:  L Lyon; L M Saksida; T J Bussey
Journal:  Psychopharmacology (Berl)       Date:  2011-11-10       Impact factor: 4.530

3.  The major brain cholesterol metabolite 24(S)-hydroxycholesterol is a potent allosteric modulator of N-methyl-D-aspartate receptors.

Authors:  Steven M Paul; James J Doherty; Albert J Robichaud; Gabriel M Belfort; Brian Y Chow; Rebecca S Hammond; Devon C Crawford; Andrew J Linsenbardt; Hong-Jin Shu; Yukitoshi Izumi; Steven J Mennerick; Charles F Zorumski
Journal:  J Neurosci       Date:  2013-10-30       Impact factor: 6.167

4.  Impaired fear memory specificity associated with deficient endocannabinoid-dependent long-term plasticity.

Authors:  Jonathan W Lovelace; Philip A Vieira; Alex Corches; Ken Mackie; Edward Korzus
Journal:  Neuropsychopharmacology       Date:  2014-01-24       Impact factor: 7.853

5.  Behavioral effects of phencyclidine on nicotine self-administration and reinstatement in the presence or absence of a visual stimulus in rats.

Authors:  Natashia Swalve; Steven T Pittenger; Rick A Bevins; Ming Li
Journal:  Psychopharmacology (Berl)       Date:  2015-04-07       Impact factor: 4.530

6.  The H3 antagonist, ciproxifan, alleviates the memory impairment but enhances the motor effects of MK-801 (dizocilpine) in rats.

Authors:  Mark E Bardgett; Megan Points; Jennifer Kleier; Meredith Blankenship; Molly S Griffith
Journal:  Neuropharmacology       Date:  2010-07-16       Impact factor: 5.250

7.  Pharmacogenetic associations of the type-3 metabotropic glutamate receptor (GRM3) gene with working memory and clinical symptom response to antipsychotics in first-episode schizophrenia.

Authors:  Jeffrey R Bishop; James L Reilly; Margret S H Harris; Shitalben R Patel; Rick Kittles; Judith A Badner; Konasale M Prasad; Vishwajit L Nimgaonkar; Matcheri S Keshavan; John A Sweeney
Journal:  Psychopharmacology (Berl)       Date:  2014-08-07       Impact factor: 4.530

8.  Aripiprazole ameliorates phencyclidine-induced impairment of recognition memory through dopamine D1 and serotonin 5-HT1A receptors.

Authors:  Taku Nagai; Rina Murai; Kanae Matsui; Hiroyuki Kamei; Yukihiro Noda; Hiroshi Furukawa; Toshitaka Nabeshima
Journal:  Psychopharmacology (Berl)       Date:  2008-08-06       Impact factor: 4.530

9.  Asenapine effects in animal models of psychosis and cognitive function.

Authors:  Hugh M Marston; Jared W Young; Frederic D C Martin; Kevin A Serpa; Christopher L Moore; Erik H F Wong; Lisa Gold; Leonard T Meltzer; Marc R Azar; Mark A Geyer; Mohammed Shahid
Journal:  Psychopharmacology (Berl)       Date:  2009-05-22       Impact factor: 4.530

10.  The brattleboro rat displays a natural deficit in social discrimination that is restored by clozapine and a neurotensin analog.

Authors:  D Feifel; S Mexal; Gilia Melendez; Philip Y T Liu; Joseph R Goldenberg; Paul D Shilling
Journal:  Neuropsychopharmacology       Date:  2009-03-25       Impact factor: 7.853

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.